U.S. lawmakers have launched an investigation into whether several large drugmakers participated in clinical trials in China that contributed to the nation's military advancement. The probe focuses on the potential dual-use nature of such research, where civilian medical studies could bolster military technology.
This inquiry underscores growing tensions between the United States and China over technology transfer and national security risks. Lawmakers are scrutinizing partnerships and data-sharing agreements that may have unintended consequences for American strategic interests.
At the center of the investigation are allegations that clinical trials conducted in China provided access to sensitive data or capabilities that could be repurposed for military applications. The specifics of which companies or trials are under review have not been publicly detailed.
The investigation could reshape how pharmaceutical companies operate overseas, particularly in countries with competing geopolitical interests. It may lead to stricter oversight of international clinical trials or new restrictions on sharing certain types of biomedical data.
Experts caution that the probe's scope and potential outcomes remain unclear, as does the direct link between these trials and military use. The drugmakers have not yet commented on the allegations.